• Je něco špatně v tomto záznamu ?

Circulating microparticles in patients with chronic hepatitis C and changes during direct-acting antiviral therapy

P. Husa, S. Snopkova, J. Zavrelova, F. Zlamal, R. Svacinka, P. Husa

. 2021 ; 165 (2) : 146-151. [pub] 20210427

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22007864

BACKGROUND: Microparticles (MPs) are heterogeneous vesicles derived from membranes of different cells. Between 70 to 90% of MPs detected in blood originate from platelets. The release of MPs is associated with proinflammatory and procoagulant states. Elevated levels of MPs have been found in different diseases. We investigated MPs levels in patients with chronic hepatitis C (CHC) and changes in level during treatment using direct-acting antivirotics (DAA). PATIENTS AND METHODS: Thirty-six patients with CHC and forty healthy volunteers were included in the study. Concentrations of MPs were determined indirectly by measuring their procoagulant activity in plasma at baseline, end of therapy (EOT), and 12 weeks after EOT when the sustained virological response was assessed (SVR12). RESULTS: All patients achieved SVR12, which was associated with rapid improvement of markers of liver damage and function as well as liver stiffness (P=0.002). MPs levels were significantly higher in CHC patients than in healthy volunteers (P<0.001). No statistically significant decrease was found observed between baseline and SVR12 (P=0,330). Analysis of subpopulations with minimal fibrosis F0-1 (P=0.647), advanced fibrosis F2-4 (P=0.370), women(P=0.847), men (P=0.164) and genotype 1 (P=0.077) showed no significant changes during the follow-up period. CONCLUSIONS: MPs levels are higher in CHC patients and remain elevated shortly after achieving SVR. Higher concentrations of MPs in plasma are probably caused by a chronic uncontrolled exaggerated inflammatory response caused by CHC. Longer observation would probably confirm the significance of MPs levels decrease because normalization of liver function, inflammation, and structure after SVR requires more than 12 weeks.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc22007864
003      
CZ-PrNML
005      
20220330125806.0
007      
ta
008      
220309s2021 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2021.023 $2 doi
035    __
$a (PubMed)33928944
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Husa, Petr $7 xx0228964 $u Department of Infectious Diseases, University Hospital Brno, Jihlavska 20, 62500 Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic
245    10
$a Circulating microparticles in patients with chronic hepatitis C and changes during direct-acting antiviral therapy / $c P. Husa, S. Snopkova, J. Zavrelova, F. Zlamal, R. Svacinka, P. Husa
504    __
$a Literatura
520    9_
$a BACKGROUND: Microparticles (MPs) are heterogeneous vesicles derived from membranes of different cells. Between 70 to 90% of MPs detected in blood originate from platelets. The release of MPs is associated with proinflammatory and procoagulant states. Elevated levels of MPs have been found in different diseases. We investigated MPs levels in patients with chronic hepatitis C (CHC) and changes in level during treatment using direct-acting antivirotics (DAA). PATIENTS AND METHODS: Thirty-six patients with CHC and forty healthy volunteers were included in the study. Concentrations of MPs were determined indirectly by measuring their procoagulant activity in plasma at baseline, end of therapy (EOT), and 12 weeks after EOT when the sustained virological response was assessed (SVR12). RESULTS: All patients achieved SVR12, which was associated with rapid improvement of markers of liver damage and function as well as liver stiffness (P=0.002). MPs levels were significantly higher in CHC patients than in healthy volunteers (P<0.001). No statistically significant decrease was found observed between baseline and SVR12 (P=0,330). Analysis of subpopulations with minimal fibrosis F0-1 (P=0.647), advanced fibrosis F2-4 (P=0.370), women(P=0.847), men (P=0.164) and genotype 1 (P=0.077) showed no significant changes during the follow-up period. CONCLUSIONS: MPs levels are higher in CHC patients and remain elevated shortly after achieving SVR. Higher concentrations of MPs in plasma are probably caused by a chronic uncontrolled exaggerated inflammatory response caused by CHC. Longer observation would probably confirm the significance of MPs levels decrease because normalization of liver function, inflammation, and structure after SVR requires more than 12 weeks.
650    _2
$a antivirové látky $x terapeutické užití $7 D000998
650    12
$a mikropartikule $7 D055252
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibróza $7 D005355
650    12
$a chronická hepatitida C $x farmakoterapie $7 D019698
650    _2
$a lidé $7 D006801
650    _2
$a zánět $7 D007249
650    _2
$a jaterní cirhóza $x farmakoterapie $7 D008103
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a setrvalá virologická odpověď $7 D000072230
655    _2
$a časopisecké články $7 D016428
700    1_
$a Snopková, Svatava, $d 1958- $7 stk2008428891 $u Department of Infectious Diseases, University Hospital Brno, Jihlavska 20, 62500 Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic
700    1_
$a Zavřelová, Jiřina $7 xx0168330 $u Department of Hematology, University Hospital Brno, Jihlavska 20, 62500 Brno, Czech Republic
700    1_
$a Zlámal, Filip $7 xx0225075 $u Research Centre for Toxic Compounds in the Environment, Masaryk University, Kamenice 5, 60200 Brno, Czech Republic
700    1_
$a Svačinka, Radek $7 xx0104694 $u Department of Infectious Diseases, University Hospital Brno, Jihlavska 20, 62500 Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic
700    1_
$a Husa, Petr, $d 1960- $7 xx0018127 $u Department of Infectious Diseases, University Hospital Brno, Jihlavska 20, 62500 Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 165, č. 2 (2021), s. 146-151
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33928944 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20220309 $b ABA008
991    __
$a 20220330125801 $b ABA008
999    __
$a ok $b bmc $g 1775501 $s 1159057
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 165 $c 2 $d 146-151 $e 20210427 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20220309

Najít záznam

Citační ukazatele

Možnosti archivace